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Background and purpose   The criteria for selecting patients who 
may benefit from surgery of spinal cord compression in meta-
static prostate cancer are poorly defined. We therefore studied 
patients operated for metastatic spinal cord compression in order 
to evaluate outcome of surgery and to find predictors of survival.
Patients and methods   We reviewed the records of 54 consecu-
tive patients with metastatic prostate cancer who were operated 
for spinal cord compression at Umeå University Hospital. The 
indication for surgery was neurological deficit due to spinal cord 
compression. 41 patients had hormone-refractory cancer and 
13 patients had previously untreated, hormone-naïve prostate 
cancer. 29 patients were operated with posterior decompression 
only, and in 25 patients posterior decompression and stabilization 
was performed.
Results   Preoperatively, 6/54 of patients were able to walk. 
1 month after surgery, 33 patients were walking, 15 were non-
ambulatory, and 6 had died. Mortality rate was 11% at 1 month, 
41% at 6 months, and 59% at 1 year. In the hormone-naïve group, 
8/13 patients were still alive with a median postoperative follow-up 
of 26 months. In the hormone-refractory group, median survival 
was 5 months. Patients with hormone-refractory disease and Kar-
nofsky performance status (KPS) of ≤ 60% had median survival 
of 2.5 months, whereas those with KPS of 70% and KPS of ≥ 80% 
had a median survival of 7 months and 18 months, respectively 
(p < 0.001). Visceral metastases were present in 12/41 patients 
with hormone-refractory tumor at the time of spinal surgery, and 
their median survival was 4 months—as compared to 10 months 
in patients without visceral metastases (p = 0.003). Complications 
within 30 days of surgery occurred in 19/54 patients. 
Interpretation   Our results indicate that patients with hor-
mone-naive disease, and those with hormone-refractory disease 
with good performance status and lacking visceral metastases, 
may be helped by surgery for metastatic spinal cord compression.
 
 
Bone metastasis occurs in more than 80% of patients with 
advanced prostate cancer, most commonly in the spine 
(Bubendorf et al. 2000). Spinal cord compression usually 
occurs in patients with advanced hormone-resistant disease, 
causing neurological complications detrimental to quality and 
duration of life (Clarke 2006). However, spinal cord compres-
sion may also be the first clinical manifestation of metastases 
in patients with previously localized disease, or may occasion-
ally be the presenting sign in patients with previously unrec-
ognized prostate cancer. Spinal cord compression in patients 
with prostate cancer has been reported to have an incidence of 
3–7% (Kuban et al. 1986, Honens de Lichtenberg et al. 1992, 
Loblaw et al. 2003).
The outcome of surgery for spinal cord compression is usu-
ally reported in series involving different tumors, making it 
difficult to draw conclusions on specific tumor types (Jans-
son and Bauer 2006, Chaichana et al. 2009). In some studies 
limited to prostate cancer, surgical treatment has been ana-
lyzed together with results of radiation treatment, with a low 
number of patients operated (Huddart et al. 1997, Cereceda et 
al. 2003, Tazi et al. 2003). There have only been a few studies 
that have specifically addressed surgical treatment of meta-
static spinal cord compression in prostate cancer (Shoskes and 
Perrin 1989, Williams et al. 2009). Furthermore, the criteria 
for selecting patients who may benefit from surgical therapy 
of spinal cord compression are poorly defined.
We therefore studied patients with prostate cancer who were 
operated for metastatic spinal cord compression to evaluate 
outcome of surgery and to find predictors of survival and neu-
rological restitution. 
Patients and methods
We reviewed the records of 54 consecutive patients with his-
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and non-skeletal metastases were treated with palliative radio-
therapy (17 patients). 5 of these patients received palliative 
radiotherapy because of continuous pain, to the same spinal 
level as the operation site, at a median interval of 5 (4–18) 
months before spinal surgery. 1 patient had radiation treat-
ment due to neurological symptoms 9 days before surgery for 
spinal cord compression. 3 patients received bisphosphonates 
(zolendronic acid) and 4 were given radioisotopes. In addi-
tion, 11 patients were on continuous therapy with low-dose 
prednisone, mainly for pain relief, for median 6 (1.5–12) 
months until the time of surgery. 
The 13 patients with hormone-naïve prostate cancer were 
treated with androgen ablation (orhiectomy 12 patients, LHRH 
agonist 1 patient) either a short time (2–7 days) before spinal 
surgery (4 patients) or immediately afterwards (9 patients). 
The anatomic location of spinal lesions was assessed by pre-
operative MR imaging (Table 2). Neurological function was 
graded according to Frankel preoperatively, and 4 weeks and 6 
months postoperatively. The preoperative functional status of 
the patients before presentation with neurological symptoms 
had been evaluated according to the Karnofsky performance 
status scale (KPS). The follow-up time was defined as the time 
between the date of operation and the latest follow-up exami-
nation or death. The median follow-up time for survivors was 
26 (7–52) months in the hormone-naïve group and 12 (7–27) 
months in the hormone-refractory group. 
metastatic spinal cord compression at Umeå 
University Hospital, Sweden, between Sep-
tember 2003 and December 2008. The mate-
rial for morphological studies was collected 
prospectively as part of a larger study on 
bone metastasis from prostate cancer, and 53 
patients from the present study were included 
in the study on androgen receptor expression 
in bone metastases (Crnalic et al. 2010). 
The study was approved by the local ethics 
review board (No. 223/03, dnr 03-185 and 
dnr 04-26M). 
The indication for surgery was neurologi-
cal deficit due to spinal cord compression. 
41 patients had already been diagnosed as 
having hormone-refractory prostate cancer, 
whereas 13 patients had previously untreated, 
hormone-naïve prostate cancer (Table 1). The 
surgical and medical therapies were not ran-
domized, and were performed according to 
the preferences of the surgical and oncology 
teams. A high dose of steroids was prescribed 
to 51 of the 54 patients after the onset of neu-
rological symptoms.
Treatment of primary prostate cancer for 
the patients in the hormone-refractory group 
consisted of androgen deprivation therapy, 
either with luteinizing hormone-releasing 
hormone (LHRH) agonists (33 patients) or 
orchiectomy (8 patients). 1 patient under-
went radical prostatectomy, and 3 patients 
received curative radiation therapy (78 Gy). 
In addition, 29 patients also received antian-
drogens. After failure of hormone treatment, 
5 patients were given chemotherapy. Skeletal 
Table 2. Anatomic localization of spinal cord compressiona 
Anatomical site  Anatomical distribution
   1 level   2 levels   3 levels   4 levels 
  
Cervical       1   
Thoracic   28  14 b  1 1  c
Lumbar     7    2
  
a Data represent number of patients.
b In two patients, 2 separate levels were involved: Th4 + Th8, 
and Th6 + Th9, respectively.
c Levels involved: C7-Th3.
Table 1. Clinical characteristics of 54 patients with prostate cancer who were operated 
for metastatic spinal cord compression (SCC) a 
   Hormone status
 Hormone-naïve b   Hormone-refractory c 
 
Clinical characteristics  (n = 13)  (n = 41)
    
Age at diagnosis of primary tumor    77 (60–85)    69 (51–86)
Age at surgery for SCC    77 (60–85)    72 (54–88)
PSA at diagnosis of primary tumor (ng/mL)  140 (21–4,000)    82 (2–7,300)
PSA at surgery for SCC (ng/mL)  140 (21–3,704)  190 (0.5–5,139) d
Interval between primary tumor diagnosis 
  and surgery for SCC (months)    0  34 (3.5–216)
Gleason score of primary tumor:   6    0    2
    7     1  14
    8    1    6
     9    1    6
   10    0    3
  Not available  10  10
Other sites of metastasis at the time of  
surgery for SCC e   
   Abdominal organs    0    3
  Pelvic organs    0    3
   Lymph nodes    0    9
   Lung    0    3
  Other bones  11  41
Preoperative Frankel grade: f   A    0    0
   B    0    3
   C  12  33
   D    1    5
   E    0    0
    
a Values are given as median (min–max) or absolute numbers (number of patients).
b Diagnosed with prostate cancer as a result of pain or neurological symptoms from 
spinal metastasis. 
c Patients with disease progression after long-term androgen deprivation therapy.
d PSA values were not available for 3 patients.
eVisceral metastases were registered in 12 patients in the hormone-refractory group.  
  Patients may have more than one metastasis.
f Grade A: complete lesion (paraplegia); grade B: only sensory function; grade C: motor 
function present but not of practical use (non-ambulatory); grade D: motor function pres-
ent, sufficient to allow walking (ambulatory); grade E: no neurological symptoms.82  Acta Orthopaedica 2011; 83 (1): 80–86
Statistics
Groups were compared with the Mann-Whitney U-test. Post-
operative survival was estimated by Kaplan-Meier analysis 
with death from prostate cancer as event. Survival curves were 
compared with the log-rank test. A p-value of ≤ 0.05 was con-
sidered statistically significant. Statistical analysis was per-
formed using GraphPad Prism software version 5.0 (Graph-
Pad Inc., San Diego, CA).
Results
Surgical procedure and postoperative treatment
29 patients were operated with posterior decompression, 
and 25 patients with posterior decompression and stabiliza-
tion with pedicle screws or with pedicle screws and hooks. 
The median operating time was 1.3 (0.6–3.2) h for posterior 
decompression and 2.7 (1.3–5.9) h for posterior decompres-
sion and stabilization. Adjuvant radiation therapy was given 
to 35 patients (11 hormone-naïve, 24 hormone-refractory) at 
a median dose of 28 (16–28) Gy and at median interval of 33 
(18–69) days postoperatively. 10 patients (1 hormone-naïve, 9 
hormone-refractory) received chemotherapy and 8 patients (1 
hormone-naïve, 7 hormone-refractory) received bisphospho-
nates postoperatively. 
Neurological function postoperatively
33 of the 54 patients were able to walk 1 month after sur-
gery (Table 3). 27 of 45 patients in the preoperative Frankel 
grade C group regained their ability to walk 4 weeks after 
Table 3. Neurological evaluation using the Frankela classification: 
preoperative values compared with those recorded 4 weeks post-
operatively
  Pre-op.   4 weeks post-op.
   n=54  b  A  B  C  D  E Dead
Hormone-refractory
 A
  B    3 b     2     1
 C  33  b     10 18    5
  D    5        5
 E
Hormone-naive
  A      
 B
  C    12     3 9
  D    1        1
 E
a See legends to Table 1.
b 6 patients with hormone refractory tumors died within 4 weeks after 
operation and are not included in 4 weeks postoperative evaluation.
Table 4. Complications of surgery for metastatic spinal cord compression that were reg-
istered in 19 of 54 patients within 30 days of surgery (patients may have more than one 
complication)
Systemic complications  n a   n b  Follow-up after surgery
Thromboembolic: stroke    1  3 months died
Pulmonary: pneumonia  1  2  1 b and 5 a months died; and 14 b months alive
  embolism    1  7 months alive
Septicemia  1    12 days died
Gastrointestinal: 
  intestinal rupture  1    10 days died  
  bleeding    1  12 days died 
Multiple organ failure  2  1  5 a, 16 b, and 28 a days died
Local complications  n a   n b   Revised c   Follow-up after surgery
Superficial wound infection  3   2  1 b   2 a, 5 a, 7 b, and 16 a months died; 
          and 14 b months alive
CSF leak  1  1  1 a,d   4 a months died; and 14 b months alive
Wound dehiscence  1  1  2   4 a and 7 b months died
Sacral pressure sores  3  1  2 a   1 a,e, 1.5 b, 2 a, and 10 a months died
 
a Posterior decompression.
b Posterior decompression and stabilization.
c In all cases, local surgical wound revision was performed, and in the patient with CSF leak-
age the dural rift was sutured and the wound was covered with musculocutaneous flap.
d Revised twice.
e Patient was also operated for pathological fracture of the left femur 10 days after spinal surgery. 
of 19 patients with ≥ 2 levels of spinal cord compression were 
ambulatory at 4 weeks. 16 of 29 patients who were operated 
with posterior decompression and 17 of 25 patients who were 
operated with posterior decompression and stabilization were 
ambulatory 4 weeks after surgery.
Complications
24 complications were recorded within 30 days of surgery 
in 19 of the 54 patients (Table 4). Systemic complications 
occurred in 9 patients, local complications in 8, and 2 patients 
surgery; 9 of them had hormone-naïve 
tumors and 18 had hormone-refractory 
tumors. 1 patient with hormone-naïve 
tumor was operated for subdural hema-
toma 1 week before spinal surgery, 
and 1 patient with hormone-refractory 
tumor suffered a stroke 3 weeks post-
operatively; none of them improved in 
neurological function (Frankel grade 
C) postoperatively. All 6 patients 
with Frankel grade D preoperatively 
retained their neurological function 
4 weeks postoperatively. None of the 
patients from the Frankel grade B 
group reached ambulatory status.
 None of the 15 patients with grade 
C at 4 weeks postoperatively improved 
neurologically on later follow-up. Of 
the 33 patients who were ambulatory at 
4 weeks, 27 were still alive at 6 months 
and 26 of them had retained their neu-
rological function, whereas 1 patient 
could not walk. 24 of 35 patients with 1 
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had both local and systemic complications. 5 of the 11 patients 
with systemic complications and 2 of the 10 patients with local 
complications also had visceral metastases at the time of sur-
gery. 1 patient with wound dehiscence had received radiation 
therapy to the operation site 9 days preoperatively. 11 patients 
who were operated with posterior decompression had com-
plications (5 systemic, 8 local) as compared to 8 patients who 
were operated with posterior decompression and stabilization 
(6 systemic, 5 local). In the hormone-naïve group, 2 patients 
had complications (2 systemic, 2 local). In the hormone-
refractory group, 17 patients had complications (9 systemic, 
11 local). The postoperative complication rate was not related 
to age (p = 0.7). 
Survival
6 patients died within 30 days of surgery. Mortality rate was 
11% at 1 month, 24% at 3 months, 41% at 6 months, and 59% 
at 1 year. At the latest follow-up, 8 patients in the hormone-
naïve group and 4 patients in the hormone-refractory group 
were still alive after median postoperative follow-up times of 
26 (7–52) months and 12 (7–27) months, respectively. In the 
hormone-naïve group, more than half of the patients were still 
alive at the latest follow-up, whereas there was a postopera-
tive median survival of only 5 (0.25–36) months in the hor-
mone-refractory group (p < 0.001) (Figure 1a). Patients with 
hormone-refractory disease and bad performance status (KPS 
≤ 60%, n = 11) had a median survival of 2.5 (0.25–5) months, 
whereas those with a KPS of 70% (n = 22) and a KPS of ≥ 
80% (n = 8) had median survival of 7 (0.3–36) and 18 (4–27) 
months, respectively (p < 0.001) (Figure 2a). In the group with 
KPS ≤ 60%, 5 patients had visceral metastases at the time of 
surgery and 7 patients suffered from complications within one 
month of surgery. 12 of 41 patients with hormone-refractory 
tumor had visceral metastases at the time of spinal surgery. 
Their median survival was 4 (0.3–10) months, as compared 
to 10 (0.25–36) months for patients without visceral metasta-
ses (p = 0.003) (Figure 2b). Patients with hormone-refractory 
tumor who were ambulatory 4 weeks after surgery generally 
had longer survival times than non-ambulatory patients, with 
median survival of 13 (2.5–36) and 2.5 (1–10) months, respec-
tively (p < 0.001) (Figure 3). Survival was not found to be 
related to age when ages of 65, 70, or 75 years were used as 
cut-off in survival analysis—either in the whole patient mate-
rial (p = 0.7, p = 0.1, and p = 0.2) or in the hormone-refractory 
group analyzed separately (p = 0.5, p = 0.9 and p = 0.8). There 
was no statistically significant difference in the survival of 
patients when the two surgical methods were compared (p = 
0.6). 
Discussion
We found that the hormone status of bone metastases, the pre-
operative performance status of the patient, and preoperative 
morbidity related to the presence of visceral metastases had an 
influence on outcome after surgery for spinal cord compres-
sion in prostate cancer. Our results also indicate that surgery 
may improve or preserve neurological function in patients 
with metastatic spinal cord compression. 
The limitations of the present study are the small number of 
patients, the fact that the surgical or medical therapy was not 
randomized, and its retrospective character (although it was 
part of a larger prospectively collected material). The strength 
of the study is that it describes surgical outcome for a specific 
tumor type in a consecutive series of patients with the same 
indication for surgery.
Figure 1. Survival for the patients with hormone-naïve (n = 13) and hormone-refractory (n = 41) prostate 
cancer after surgery for spinal cord compression (left), and after diagnosis of the primary tumor (right).
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Only one tenth of the patients in our study were able to walk 
preoperatively. 1 month after surgery, more than half of them 
were walking. Neurological deficit was the only inclusion cri-
terion in this study, whereas intractable pain with or without 
deformity or impaired neurological function were inclusion 
criteria in the other 2 studies on surgical treatment of spinal 
cord compression in prostate cancer. Shoskes and Perrin 
(1989) reported on 28 patients and Williams et al. (2009) 
reported on 44 patients; both studies included patients with 
previously treated prostate cancer. Unlike our patients, 32 of 
44 (Williams et al. 2009) and 15 of 28 (Shoskes and Perrin 
1989) were ambulatory preoperatively. 8 of 12 patients in the 
study by Williams et al. (2009) and 8 of 13 patients in the 
study by Shoskes and Perrin (1989) who were non-ambulatory 
preoperatively regained their ability to walk postoperatively, 
rates which are similar to the 27/48 patients in our study. 
Median survival in patients with hormone-refractory tumors in 
our study was 5 months—the same as in the series of Williams 
et al. (2009), suggesting similar disease burden. Our patients 
are comparable to those of Jansson and Bauer (2006), who 
reported on surgical outcome of spinal cord compression in 
282 patients with different tumors. Two-thirds of their patients 
could not walk before surgery and 23% had visceral metas-
tases. 40% of the patients had prostate cancer with results on 
survival similar to our results. The complication and mortality 
rates in our study are similar to those reported in a population-
based study of surgery for spinal metastases in 987 patients, 
137 of whom had prostate cancer (Finkelstein et al. 2003). 
Prolonged functional independence may potentially improve 
quality of life and survival in carefully selected patients. Thus, 
the results of our study—as in other retrospective and pro-
spective observational studies—demonstrate a longer median 
survival time in patients who are able to walk after surgery or 
Figure 3. Survival for the patients with hormone-refractory prostate 
cancer (n = 35) a according to ambulatory status 4 weeks after surgery 
for spinal cord compression. 
a 6 of 41 patients died within 4 weeks of surgery and were not included 
in the survival analysis related to ambulatory status.
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Figure 2. Survival for the patients with hormone-refractory prostate cancer (n = 41) according to Karnofsky 
performance status a,b (KPS) (left), and presence of visceral metastasis (right).
a 100: normal, no complaints, no evidence of disease; 90: able to carry on normal activity, minor signs of 
symptoms of disease; 80: normal activity with effort, some signs or symptoms of disease; 70: cares for self, 
unable to carry on normal activity or to do any work; 60: requires occasional assistance from others but able 
to care for most of own needs; 50: requires considerable assistance from others and frequent medical care; 
40: disabled, requires special care and assistance; 30: severely disabled, hospitalization indicated, death not 
imminent; 20: very sick, hospitalization necessary, active supportive treatment necessary; 10: moribund; 0: 
dead.
b No patients had KPS less than 50%.
0 12 24 36
0
50
100
KPS 80–100%
KPS 70%
KPS 50–60%
Time after surgery (months)
Overall survival (%)
0 12 24 36
0
50
100
yes
no
Visceral metastasis
Time after surgery (months)
Overall survival (%)Acta Orthopaedica 2011; 83 (1): 80–86  85
radiotherapy than in non-ambulatory patients (Hill et al. 1993, 
Hirabayashi et al. 2003, Helweg-Larsen et al. 2000). 
Regarding preservation of neurological function, several 
authors have reported the advantages of surgery combined 
with radiation, or surgery alone, compared with radiation 
alone (Klimo et al. 2005, Patchell et al. 2005). One prospec-
tive, randomized trial showed that decompressive surgery plus 
radiation is favorable for both preservation and regaining of 
ambulatory function compared to radiation alone, but even in 
these highly selected patients median survival was only 4.2 
months (Patchell et al. 2005). Furthermore, when the same 
data were stratified according to age, the authors found that 
at ≥ 65 years the beneficial effect of surgery fades to become 
equivalent to that of radiation therapy alone (Chi et al. 2009). 
Many patients with advanced prostate cancer are elderly, 
and have limited physiological reserve. The presence of vis-
ceral metastases will further depress their tolerance to surgery 
and render them susceptible to complications, thus having 
a potentially negative effect on survival (Bauer and Wedin 
1995). In our study, patients with bad performance status 
and those with visceral metastasis had worse survival. Thus, 
5 of 11 patients with KPS of ≤ 60 had visceral metastases 
and 7 of these 11 patients had complications after surgery. 
Furthermore, in our previous study high preoperative serum 
PSA, probably related to heavy tumor burden, was found to 
be associated with shorter survival in patients with hormone-
refractory tumors (Crnalic et al. 2010). 
In the present study, patients with hormone-naïve tumors 
had good functional outcome and two-thirds were still alive 
at the latest follow-up. Indeed, using the primary tumor diag-
nosis as a starting point in survival analysis, the expected 
postoperative survival for this patient group could be simi-
lar to the survival of the hormone-refractory group after pri-
mary diagnosis (Figure 1b). The effect of acute orchiectomy 
on reduction of spinal tumor volume and improvement of 
functional outcome in these patients should not be underesti-
mated. However, in 4 of our patients neurological symptoms 
continued to progress despite acute orchiectomy, thus lead-
ing to spinal surgery after 2–7 days. There have been few 
reports on hormone-naïve prostate cancer with spinal cord 
compression. Huddart et al. (1997) reported on 17 patients. 
13 were operated and 4 received radiotherapy, with a median 
survival of 1.7 years after treatment. These authors concluded 
that the absence of prior hormone therapy was a prognostic 
factor for better survival. In a study by Jansson and Bauer 
(2006), 13 patients with previously untreated prostate cancer 
had a survival rate of 62% two years after surgery for spinal 
cord compression, which is similar to our results. However, 
results of radiotherapy alone for spinal cord compression in 
37 patients with hormone-naïve prostate cancer showed com-
parably poor median survival (11 months) and worse func-
tional outcome (only 6 of 37 patients had improved motor 
function) than for the patients with known metastatic disease 
(Rades et al. 2006).
In summary, our findings indicate that patients with hor-
mone-naïve disease and those with hormone-refractory dis-
ease with good performance status and no visceral metastases 
may be helped by surgery for metastatic spinal cord compres-
sion. 
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